# Proximal Ventures Raises $27.5 Million for AI Drug Development

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/54378
Published: 2026-11-11T19:47:25.000Z
Updated: 2026-11-11T19:47:25.000Z
Section: Business

> Its planned investments range from $500,000 to $1.5 million, and the firm has already backed seven startups.

Proximal Ventures has raised a $27.5 million debut fund for startups using artificial intelligence to support pharmaceutical research and drug development. The firm plans to invest $500,000 to $1.5 million in pre-seed and seed-stage companies and has backed seven startups so far.

One of them is ChronicleBio, which uses AI to analyze biological and medical information related to chronic diseases and possible treatments. Proximal is targeting work that pharmaceutical companies have often hired specialist providers to do, including synthesizing molecular compounds, scaling drug manufacturing and analyzing clinical trial data.

The fund’s backers include SignalFire, Kleiner Perkins and Bertelsmann Healthcare Investments. Individual investors include Dimension Capital co-founders Nan Li and Zavain Dar, and Amy Abernethy, co-founder of Highlander Health and a former principal deputy commissioner of the Food and Drug Administration.